Top Page
PreveCeutical Medical
(OTC:PREV)
PreveCeutical Medical (PREV) vs. S&P 500 (SPY)
PreveCeutical Medical Business Overview & Revenue Model
PreveCeutical Medical Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.03K | Gross Profit |
| -7.47K | -9.86K | -9.89K | -5.09K | -75.17K | 2.25K | EBIT |
| -1.01M | -963.12K | -1.10M | -897.85K | -2.14M | -3.51M | EBITDA |
| -1.02M | -955.09K | -1.03M | -1.28M | -2.08M | -2.83M | Net Income Common Stockholders |
| -1.36M | -1.27M | -1.48M | -1.73M | -3.80M | -3.58M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 64.89K | 1.43K | 5.62K | 16.06K | 156.44K | 28.48K | Total Assets |
| 2.23M | 181.51K | 189.14K | 161.20K | 302.45K | 857.64K | Total Debt |
| 4.49M | 3.83M | 3.23M | 2.93M | 3.01M | 4.75M | Net Debt |
| 4.42M | 3.83M | 3.23M | 2.91M | 2.86M | 4.72M | Total Liabilities |
| 5.29M | 5.96M | 4.82M | 4.27M | 3.91M | 5.34M | Stockholders Equity |
| -3.06M | -5.78M | -4.64M | -4.10M | -3.60M | -4.49M |
| Cash Flow | Free Cash Flow | ||||
| -399.04K | -296.97K | -222.64K | -481.59K | 61.94K | -995.27K | Operating Cash Flow |
| -397.96K | -296.97K | -222.64K | -426.39K | 64.59K | -993.94K | Investing Cash Flow |
| -1.08K | 0.00 | 850.00 | -52.70K | -2.65K | -1.33K | Financing Cash Flow |
| 399.21K | 293.62K | 211.72K | 136.75K | 184.46K | 867.02K |
PreveCeutical Medical Technical Analysis
PreveCeutical Medical Peers Comparison
PreveCeutical Medical Corporate Events
PreveCeutical Medical Inc. has announced a non-brokered private placement of up to 10 million units at $0.03 per unit, aiming to raise gross proceeds of up to $300,000. The proceeds will be used for paying outstanding payables, operating expenses, and general working capital. This strategic financial maneuver could potentially strengthen the company’s operational capabilities and enhance its market positioning in the health sciences industry, subject to certain conditions including CSE approval.
PreveCeutical Medical Inc.’s subsidiary, BioGene Therapeutics, has announced its participation in the 43rd JP Morgan Healthcare Conference, aiming to showcase its work in metabolic health and gene-based treatments. The participation of BioGene’s leadership team at this prestigious event underscores the company’s commitment to advancing its position in the life sciences industry and highlights its ongoing research efforts, particularly in addressing diabetes and obesity through innovative therapies.
PreveCeutical Medical’s subsidiary, BioGene Therapeutics, has appointed Dr. Barry Ticho to its Scientific Advisory Board, leveraging his seasoned expertise in drug development and biotechnology. Dr. Ticho’s impressive career includes leadership roles at Stoke Therapeutics and contributions to companies like Verve and Moderna, marking significant advancements in treating various diseases. This strategic appointment is expected to enhance BioGene’s initiatives in developing innovative therapies.
PreveCeutical Medical Inc.’s subsidiary, BioGene Therapeutics, has appointed Dr. Brian Gallagher, Jr. to its Corporate Advisory Board, bringing his expertise in venture capital and corporate development. Gallagher’s extensive experience in biotech investments and successful leadership in high-profile exits, like the acquisition of Translate Bio by Sanofi, is expected to drive BioGene’s growth in innovative therapies.
PreveCeutical Medical’s subsidiary, BioGene Therapeutics, has appointed Stephen Glover to its Board of Directors, leveraging his extensive leadership experience in the biopharma industry to advance their mission of developing groundbreaking therapies. Glover, known for his successful track record in corporate strategy and financial management, is expected to significantly contribute to the company’s growth and innovation.
PreveCeutical Medical’s subsidiary, BioGene Therapeutics, has appointed Professor Mirela Delibegovic to its Scientific Advisory Board, enhancing their expertise in metabolic health research. Her extensive background in diabetes and obesity research is expected to significantly contribute to BioGene’s innovative therapeutic programs.
PreveCeutical Medical’s subsidiary, BioGene Therapeutics, appoints Dr. Linnea Olofsson as Chief Scientific Officer and Dr. Harry Parekh as Chief Research Officer to advance its drug and gene delivery technologies. These strategic appointments are expected to drive innovation and growth in the life sciences sector, positioning the company for future success.
PreveCeutical Medical has successfully closed a transaction involving the sale of intellectual property assets to its subsidiary, BioGene Therapeutics, for a total of USD$1,353,227. The deal includes a cash payment and the issuance of 16 million common shares of BioGene, with plans to distribute some of these shares to shareholders. This strategic move could potentially enhance PreveCeutical’s financial position and shareholder value.
PreveCeutical Medical’s subsidiary, BioGene Therapeutics, has appointed Dr. Mariya Georgieva as President to lead advancements in siRNA therapy for diabetes and obesity. Dr. Georgieva brings valuable experience from AstraZeneca, enhancing BioGene’s research capabilities in metabolic health and gene-based treatments.